Abstract: A method and apparatus for detecting pathogens and particles in a fluid in which particle size and intrinsic fluorescence of a simple particle is determined.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
February 11, 2014
Assignee:
Azbil BioVigilant, Inc.
Inventors:
Jian-Ping Jiang, Michael Morrell, Gregory Scott Morris
Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and collecting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.
Type:
Grant
Filed:
December 24, 2009
Date of Patent:
February 11, 2014
Assignee:
The Chemo-Sero-Therapeutic Research Institute
Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
Type:
Grant
Filed:
October 9, 2009
Date of Patent:
January 28, 2014
Assignees:
President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's Hospital
Inventors:
Frank Alexis, Matteo Iannacone, Jinjun Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
Abstract: The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
January 14, 2014
Assignee:
Medical Service Consultation International, LLC
Abstract: An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan.
Type:
Grant
Filed:
August 28, 2007
Date of Patent:
December 31, 2013
Assignee:
Ortho-Clinical Diagnostics, Inc.
Inventors:
Banumathi Sankaran, Sheryl S. Sullivan, Darrell C. Haynes, Philip C. Hosimer, Graham Yearwood
Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
November 20, 2012
Date of Patent:
December 10, 2013
Assignee:
Novozymes A/S
Inventors:
Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
May 30, 2012
Date of Patent:
December 10, 2013
Assignee:
Novozymes A/S
Inventors:
Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
September 24, 2013
Assignee:
Techlab, Inc.
Inventors:
James H. Boone, David M. Lyerly, Tracy D. Wilkins
Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
October 8, 2012
Date of Patent:
August 13, 2013
Assignee:
Novozymes A/S
Inventors:
Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentiaily present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.
Type:
Grant
Filed:
March 8, 2004
Date of Patent:
August 13, 2013
Assignee:
GeneOhm Sciences, Inc.
Inventors:
Jean-Pierre Hermet, Isabelle Besson-Faure, Sébastien Ribault, Yann Godfrin, Anne Monnot des Angles
Abstract: Methods are described for detecting reaction components with affect a reaction. Biomolecules such as enzymes can be addressed at the single molecule level in order to discover function, detect binding partners or inhibitors, and/or measure rate constants.
Type:
Grant
Filed:
February 16, 2007
Date of Patent:
July 23, 2013
Assignee:
The Trustees of Tufts College
Inventors:
David R. Walt, David M. Rissin, Hans-Heiner Gorris
Abstract: The present invention provides an immunogenic composition comprising one or more Streptococcus uberis sortase-anchored surface proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.
Abstract: Arrays of single cells and methods of producing an array of single cells are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single cell capture, detection and quantitation.
Abstract: Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation.
Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
Abstract: An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.
Type:
Grant
Filed:
May 13, 2009
Date of Patent:
May 14, 2013
Assignee:
Cayman Chemical Company, Incorporated
Inventors:
Nisha Palackal, Jeffrey K. Johnson, Karie L. McGowan, Kirk W. Maxey, Gregory W. Endres
Abstract: A bioengineering, in particular to develop novel probiotic preparations based on Bacillus-strain bacteria, which can be used for preventing and treating infectious diseases and disbiosis of a human being, farm animals and birds. The novel strains of B. subtilis 07 (VKPM No. B-8611) and B. licheniformis 09 (VKPM No. B-8610) exhibit a broad spectrum of antagonistic activity, high proteolytic and amylase activity and a distinct ability in terms of a lysozim production. Such strains do not compete with each other but enter into synergistic relations in the form of an increased antagonistic action of the biopreparation. The inventive biopreparation comprises the B. subtilis 07 VKPM No. B-8611 and B. licheniformis 09 VKPM No. B-8610 strains and a protective medium. Such biopreparation can also contain a solvent and/or filler and exhibits an increased antagonistic activity with respect to a wide range of pathogenic and opportunistic pathogenic microorganisms and a resistance to quite a number of antibiotics.
Type:
Grant
Filed:
April 28, 2005
Date of Patent:
April 9, 2013
Inventors:
Irina Grigorievna Osipova, Irina Borisovna Sorokulova, Elena Aleksandrovna Vasilieva, Sergei Gennadievich Trofimov, Vera Franzevna Evlashkina, Elena Yurievna Haritonova, Sergei Eduardovich Sarkisov, Natalia Vasilievna Tereshkina, Yurii Igorevich Ostroumov, Aleksandr Nikolaevich Doronin, Marina Aleksandrovna Kulichizkaya, Aleksandr Aleksandrovich Matveev
Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.
Type:
Grant
Filed:
December 22, 2011
Date of Patent:
March 19, 2013
Assignee:
Polytopos LLC
Inventors:
Michael W Deem, Jeong-Man Park, Hao Zhou
Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.
Type:
Grant
Filed:
August 17, 2012
Date of Patent:
March 5, 2013
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu